Every SEC Form 3/4/5 on record for this filer (CIK 1680739) — 7 issuers, 79 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | Director | 2018-08-02 → 2026-06-30 | 32 | −$8M |
| TVTX | Travere Therapeutics, Inc. | Director | 2021-05-18 → 2026-06-16 | 13 | −$3M |
| NRIX | Nurix Therapeutics, Inc. | Director | 2025-03-13 → 2026-05-15 | 4 | — |
| EIKN | Eikon Therapeutics, Inc. | Chief Medical Officer | 2026-02-04 → 2026-03-04 | 2 | — |
| AARD | Aardvark Therapeutics, Inc. | Director | 2025-02-12 → 2025-06-13 | 2 | — |
| ATRA | Atara Biotherapeutics, Inc. | Director · lapsed | 2018-09-12 → 2022-06-27 | 6 | — |
| RTRX | Retrophin, Inc. | Director · lapsed | 2016-07-26 → 2020-05-19 | 6 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| TVTX | 2026-06-12 | Sell | 4,500 | $50.00 | $225,000 | 41,500 |
| TVTX | 2026-05-05 | Sell | 4,500 | $46.65 | $209,925 | 37,500 |
| TVTX | 2026-05-01 | Sell | 9,750 | $44.22 | $431,145 | 37,500 |
6 of 7 issuers are covered and open a security page; the rest are on file here only.
